Appendix Table F37. Perceived treatment success after different doses of duloxetine

Reference sample size	Outcome	Subgroup	Daily dose	Events in active/ randomized	Events in control/ randomized	Relative Risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 Treated
Norton, 2002[355] 275	PGI-I score Percent in "very much" or "much better" categories	Baseline IEF ≥14	20 vs. 40mg/day	29/138	56/138	0.51 (0.35; 0.75)	-0.20 (-0.31; -0.09)	-5 (-11; -3)	-199 (-305; -92)
Norton, 2002[355] 275	Increase in avoidance/limiting domain of I-QOL score from baseline		20 vs. 40mg/day	4/138	14/138	0.28 (0.10; 0.84)	-0.07 (-0.13; -0.02)	-14 (-65; -8)	-73 (-131; -15)
Norton, 2002[355] 275	Increase in psychosocial domain of I-QOL score from baseline		20 vs. 40mg/day	4/138	10/138	0.40 (0.13; 1.24)	-0.04 (-0.10; 0.01)		
Norton, 2002[355] 275	Increase in social embarrassment domain of I-QOL score from baseline		20 vs. 40mg/day	5/138	16/138	0.31 (0.12; 0.82)	-0.08 (-0.14; -0.02)	-12 (-54; -7)	-81 (-143; -18)
Norton, 2002[355] 278	PGI-I score Percent in "very much" or "much better" categories		20 vs. 80mg/day	29/138	70/138	0.42 (0.29; 0.60)	-0.29 (-0.40; -0.18)	-3 (-5; -3)	-290 (-397; -183)
Norton, 2002[355] 278	Increase in avoidance/limiting domain of I-QOL score from baseline		20 vs. 80mg/day	4/138	20/138	0.20 (0.07; 0.58)	-0.11 (-0.18; -0.05)	-9 (-20; -6)	-114 (-178; -50)
Norton, 2002[355] 278	Increase in psychosocial domain of I-QOL score from baseline		20 vs. 80mg/day	4/138	16/138	0.25 (0.09; 0.74)	-0.09 (-0.14; -0.03)	-12 (-39; -7)	-85 (-145; -26)
Norton, 2002[355] 278	Increase in social embarrassment domain of I-QOL score from baseline		20 vs. 80mg/day	5/138	21/138	0.24 (0.09; 0.62)	-0.11 (-0.18; -0.05)	-9 (-21; -6)	-114 (-181; -47)
Norton, 2002[355] 277	PGI-I score Percent in "very much" or "much better" categories		40 vs. 80mg/day	56/137	70/137	0.82 (0.63; 1.06)	-0.09 (-0.21; 0.03)		

Appendix Table F37. Perceived treatment success after different doses of duloxetine (continued)

Reference sample size	Outcome	Sub-group	Daily dose	Events in active/ randomized	Events in control/ randomized	Relative Risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 Treated
Norton, 2002[355] 277	Increase in avoidance/limiting domain of I-QOL score from baseline		40 vs. 80mg/day	14/137	20/137	0.72 (0.38; 1.36)	-0.04 (-0.12; 0.04)		
Norton, 2002[355] 277	Increase in psychosocial domain of I-QOL score from baseline		40 vs. 80mg/day	10/137	16/137	0.64 (0.30; 1.36)	-0.04 (-0.11; 0.03)		
Norton, 2002[355] 277	Increase in social embarrassment domain of I-QOL score from baseline		40 vs. 80mg/day	16/137	21/137	0.78 (0.42; 1.43)	-0.03 (-0.11; 0.05)		
Duckett, 2007[285] 222	PGI-I score: very much better	in stress vs. mixed UI	60 vs. 40mg twice daily	10/123	8/123	1.01 (0.41; 2.45)	0.00 (-0.07; 0.07)		
Duckett, 2007[285] 222	PGI-I score: much better	in stress vs. mixed UI	60 vs. 40mg twice daily	22/123	11/123	1.61 (0.82; 3.16)	0.07 (-0.02; 0.16)		
Duckett, 2007[285] 222	PGI-I score: a little better	in stress vs. mixed UI	60 vs. 40mg twice daily	15/123	14/123	0.86 (0.44; 1.70)	-0.02 (-0.11; 0.07)		
Duckett, 2007[285] 222	PGI-I score: no change	in stress vs. mixed UI	60 vs. 40mg twice daily	21/123	10/123	1.69 (0.84; 3.42)	0.07 (-0.02; 0.16)		
Duckett, 2007[285] 222	PGI-I score: a little worse	in stress vs. mixed UI	60 vs. 40mg twice daily	1/123	3/123	0.27 (0.03; 2.54)	-0.02 (-0.06; 0.02)		
Duckett, 2007[285] 222	PGI-I score: much worse	in stress vs. mixed UI	60 vs. 40mg twice daily	1/123	3/123	0.27 (0.03; 2.54)	-0.02 (-0.06; 0.02)		
Duckett, 2007[285] 222	PGI-I score: very much worse	in stress vs. mixed UI	60 vs. 40mg twice daily	0/123	1/123	0.27 (0.01; 6.53)	-0.01 (-0.04; 0.02)		
Duckett, 2007[285] 222	PGI-I score: total	in stress vs. mixed UI	60 vs. 40mg twice daily	70/123	50/123	1.13 (0.88; 1.44)	0.06 (-0.07; 0.20)		
Bump, 2003[108] 277	Mixed urinary incontinence		40 vs. 0mg/day	85/137	88/137	0.99 (0.82; 1.18)	-0.01 (-0.12; 0.11)		

Appendix Table F37. Perceived treatment success after different doses of duloxetine (continued)

Reference sample size	Outcome	Sub-group	Daily dose	Events in active/ randomized	Events in control/ randomized	Relative Risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 Treated
Bump, 2003[108] 277	Stress urinary incontinence		40 vs. 80mg twice daily	79/137	91/137	0.89 (0.74; 1.07)	-0.07 (-0.19; 0.04)		